Lipocine is trading 10.4% lower at $1.97 after a sharp reversal following a volatile session; no confirmed company-specific overnight catalyst was found.
- That compares with its October 7 close of $2.20.
- On October 7, Lipocine announced Health Canada approval of TLANDO through licensing partner Verity; this does not establish the reason for the October 8 decline.
- Broader markets are weaker pre-market, with provided index moves below 0.5%; any connection to Lipocine’s decline is unconfirmed.